카지노 바카라 Biologics unveils ‘카지노 바카라 Organoids’ new service to boost order competitiveness

[by Lee, Young Sung] Samsung Biologics is broadening its business scope from traditional contract development and manufacturing (CDMO) to include contract research organization (CRO) services, aiming to enhance its competitive edge in securing new orders.

카지노 바카라 Biologics announced on June 16 the launch of '카지노 바카라 Organoids,' a drug screening platform based on organoid technology. The initiative aims to create an 'early lock-in' effect by starting collaborative partnerships with clients from the initial stages of new drug candidate discovery.

The company intends to offer a next-level, high-quality organoid service by leveraging its advanced sample processing and comprehensive data management capabilities. 카지노 바카라 Biologics brings extensive experience in Good Manufacturing Practice (GMP) operations, having secured 359 manufacturing approvals from major global regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

In the organoid business, 카지노 바카라 Biologics is prioritizing the screening of anticancer drug candidates using 'cancer-derived-organoids.' This approach is intended to replace traditional cell and animal models, which present limitations such as low physiological relevance to patients, high costs, and ethical concerns.

Organoids, named by combining 'organ' with the suffix '-oid,' meaning 'resembling,’ refer to 'miniature organ models' cultured by three-dimensional aggregation of stem cells or tissue-derived cells. They have recently garnered significant market attention due to their ability to more accurately and rapidly assess the efficacy and toxicity of drug candidates, offering up to 85% similarity to actual patient tissues while remaining more cost-effective than conventional experimental methods.

According to market research firm Research and Markets, the global market for patient-derived organoids is projected to grow from USD 1 billion (approximately KRW 1.3678 trillion) in 2024 to USD 3.3 billion by 2030, reflecting an average annual rate of 22%. Industry growth is expected to accelerate further following the FDA announcement in April of its plan to reduce reliance on animal testing and actively promote organoids as an alternative model.

With the introduction of its organoid service, 카지노 바카라 Biologics aims to accelerate its strategic growth trajectory toward becoming a 'global top-tier CDMO.' Anchored in its 'three-axis growth strategy' of 'production capacity expansion portfolio diversification, and global base expansion', the company plans to continue investing in broadening its service offerings. This includes not only organoids but also antibody-drug conjugates (ADCs) and adeno-associated viruses (AAVs).

“By delivering rapid and accurate screening services from the early stages of development, we anticipate a significant reduction in our clients’ development risks and a corresponding acceleration in their timelines,” said John Rim, CEO of 카지노 바카라 Biologics. “We remain committed to developing innovative technologies and services that address the diverse needs of our clients, with the ultimate goal of ensuring their satisfaction,” he added.